Given that EGFR is overexpressed or mutated in most NSCLC cases, leading to an increased EGFR phosphorylation, and that acquired resistance to EGFR TKIs is commonly observed in NSCLC patients who initially respond to these drugs, honokiol is a promising agent for the prevention and therapy of pulmonary malignancies associated with EGFR deregulation alone or in combination with EGFR TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.